This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Lu-177-DOTATATE showed a median progression-free survival of 28.4 months compared to 8.5 months for octreotide LAR.
Why it matters
These advancements in PRRT could significantly improve treatment outcomes for patients with neuroendocrine tumors, offering new hope for better management of the disease.
How the study worked
The study reviews clinical trials and ongoing research comparing different treatment approaches for NETs.
What this study cannot tell us
The study primarily reviews existing data and ongoing trials, lacking direct experimental results from new therapies.
Read the original research
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Frontiers in endocrinology, 13, 941832
Citation
Harris, Philip E; Zhernosekov, Konstantin. (2022). The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?. Frontiers in endocrinology, 13, 941832. https://doi.org/10.3389/fendo.2022.941832